First biosimilar filgrastims launched in Japan
This article was originally published in Scrip
Executive Summary
The first biosimilar recombinant filgrastim products have been granted reimbursement and launched in Japan, in a move that looks set to put pressure on branded original granulocyte colony-stimulating factor (G-CSF) preparations.